// App-Quantinova.ai

TCT-545 : Individualizing DAPT Duration after Coronary Stenting for Patients at High Bleeding Risk – The LEADERS FREE trade-off score

Researchers

Presenter

  • Philip Urban

Principal Investigators

  • John Gregson

  • Philipp Lurz

  • Bernard Chevalier

  • Marie-Claude Morice

  • Janusz Lipiecki

  • Franz-Josef Neumann

  • Stephen Lee

  • Andrejs Erglis

  • Samantha Greene

  • Stuart Pocock

Medical Centers

  • CERC, Massy, France

  • Queen Mary Hospital, The University of Hong K, Hong Kong, Hong Kong, China

  • P. Stradins Clinical University Hospital, Riga, Latvia

  • London School of Hygiene and Tropical Medicine, London, United Kingdom

  • La Tour Hospital, Geneva, Switzerland

  • Clinique Des Domes-Pole Sante Republique, Clermont-Ferrand, France

  • Institut Cardiovasculaire Paris Sud, Massy, France

  • Heart Centre Leipzig, Leipzig, Germany

  • Universitaets-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany

Locations

  • France

  • United States

  • Germany

  • Switzerland

  • United Kingdom

  • Latvia

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Biolimus A9

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved